Delphinidins are blue-red plant pigments concentrated in maqui berries, bilberries, and blackcurrants, used as oral dietary supplements for post-meal blood sugar control, blood vessel flexibility, and tear production. Human trials test berry extracts rather than isolated delphinidins, providing low-level, indirect, mostly industry-funded evidence, with conflicted cholesterol and long-term blood sugar results. Oral extracts report zero serious adverse events, with attention centered on pre-meal timing and iron separation. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting Plasma Glucose and 1-Hour Postprandial Glucose | Fasting: 70–99 mg/dL; 1-hour post-meal: reduction from baseline | Efficacy marker expected to decrease and safety check for low blood sugar (<70 mg/dL) |
| Fasting Serum Insulin and HOMA-IR | Fasting insulin: 2–20 µIU/mL; HOMA-IR: reduction from baseline | Efficacy marker expected to decrease as postprandial and fasting insulin demand declines |
| HbA1c | <5.7% | Efficacy marker over 12 weeks in prediabetes and safety check with antidiabetic drugs |
| Fasting Lipid Panel (LDL-C, HDL-C, Triglycerides) | LDL-C <100 mg/dL (<2.59 mmol/L); HDL-C ≥40 mg/dL (≥1.03 mmol/L); Triglycerides <150 mg/dL (<1.70 mmol/L) | Efficacy marker expected to change based on delphinidin-predominant trial meta-analyses |
| Brachial FMD and Carotid-Femoral PWV | Increase in FMD and reduction in PWV from baseline | Efficacy markers for blood vessel widening and reduced arterial stiffness |
| Schirmer's Test and Dry Eye Symptom Scores | Increase in Schirmer's wetting length and reduction in symptom scores from baseline | Efficacy markers when targeting tear secretion and eye dryness |
Cadence: Baseline (after 8–12 h fast, plus vascular ultrasound or Schirmer's test); 1–2 weeks for capillary glucose with antidiabetic therapy; 4 weeks for postprandial glucose, tear production, and gastrointestinal tolerability; 12 weeks and every 6 months thereafter for HbA1c, lipids, and endothelial changes.